ECDD-S16 targets vacuolar ATPase: A potential inhibitor compound for pyroptosis-induced inflammation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
06
2023
accepted:
18
09
2023
medline:
29
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
epublish
Résumé
Cleistanthin A (CA), extracted from Phyllanthus taxodiifolius Beille, was previously reported as a potential V-ATPase inhibitor relevant to cancer cell survival. In the present study, ECDD-S16, a derivative of cleistanthin A, was investigated and found to interfere with pyroptosis induction via V-ATPase inhibition. This study examined the ability of ECDD-S16 to inhibit endolysosome acidification leading to the attenuation of pyroptosis in Raw264.7 macrophages activated by both surface and endosomal TLR ligands. To elucidate the activity of ECDD-S16 on pyroptosis-induced inflammation, Raw264.7 cells were pretreated with the compound before stimulation with surface and endosomal TLR ligands. The release of lactate dehydrogenase (LDH) was determined by LDH assay. Additionally, the production of cytokines and the expression of pyroptosis markers were examined by ELISA and immunoblotting. Moreover, molecular docking was performed to demonstrate the binding of ECDD-S16 to the vacuolar (V-)ATPase. This study showed that ECDD-S16 could inhibit pyroptosis in Raw264.7 cells activated with surface and endosomal TLR ligands. The attenuation of pyroptosis by ECDD-S16 was due to the impairment of endosome acidification, which also led to decreased Reactive Oxygen Species (ROS) production. Furthermore, molecular docking also showed the possibility of inhibiting endosome acidification by the binding of ECDD-S16 to the vacuolar (V-)ATPase in the region of V0. Our findings indicate the potential of ECDD-S16 for inhibiting pyroptosis and prove that vacuolar H+ ATPase is essential for pyroptosis induced by TLR ligands.
Sections du résumé
BACKGROUND
BACKGROUND
Cleistanthin A (CA), extracted from Phyllanthus taxodiifolius Beille, was previously reported as a potential V-ATPase inhibitor relevant to cancer cell survival. In the present study, ECDD-S16, a derivative of cleistanthin A, was investigated and found to interfere with pyroptosis induction via V-ATPase inhibition.
OBJECTIVE
OBJECTIVE
This study examined the ability of ECDD-S16 to inhibit endolysosome acidification leading to the attenuation of pyroptosis in Raw264.7 macrophages activated by both surface and endosomal TLR ligands.
METHODS
METHODS
To elucidate the activity of ECDD-S16 on pyroptosis-induced inflammation, Raw264.7 cells were pretreated with the compound before stimulation with surface and endosomal TLR ligands. The release of lactate dehydrogenase (LDH) was determined by LDH assay. Additionally, the production of cytokines and the expression of pyroptosis markers were examined by ELISA and immunoblotting. Moreover, molecular docking was performed to demonstrate the binding of ECDD-S16 to the vacuolar (V-)ATPase.
RESULTS
RESULTS
This study showed that ECDD-S16 could inhibit pyroptosis in Raw264.7 cells activated with surface and endosomal TLR ligands. The attenuation of pyroptosis by ECDD-S16 was due to the impairment of endosome acidification, which also led to decreased Reactive Oxygen Species (ROS) production. Furthermore, molecular docking also showed the possibility of inhibiting endosome acidification by the binding of ECDD-S16 to the vacuolar (V-)ATPase in the region of V0.
CONCLUSION
CONCLUSIONS
Our findings indicate the potential of ECDD-S16 for inhibiting pyroptosis and prove that vacuolar H+ ATPase is essential for pyroptosis induced by TLR ligands.
Identifiants
pubmed: 38011122
doi: 10.1371/journal.pone.0292340
pii: PONE-D-23-19268
pmc: PMC10681236
doi:
Substances chimiques
Vacuolar Proton-Translocating ATPases
EC 3.6.1.-
cleistanthin
25047-48-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0292340Informations de copyright
Copyright: © 2023 Ekchariyawat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
EMBO Rep. 2020 Nov 5;21(11):e50829
pubmed: 33124769
Oncol Rep. 2018 Mar;39(3):921-928
pubmed: 29328465
Nature. 2008 Dec 4;456(7222):658-62
pubmed: 18820679
PLoS Pathog. 2018 Dec 27;14(12):e1007519
pubmed: 30589883
Anal Biochem. 1982 Oct;126(1):131-8
pubmed: 7181105
Cell Immunol. 2012;274(1-2):121-9
pubmed: 22341560
J Immunol. 2011 Jul 15;187(2):613-7
pubmed: 21677136
Trends Biochem Sci. 2015 Oct;40(10):611-622
pubmed: 26410601
Nature. 2015 Oct 29;526(7575):660-5
pubmed: 26375003
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W537-41
pubmed: 22570416
J Mol Cell Biol. 2019 Dec 19;11(12):1069-1082
pubmed: 30860577
Nature. 2012 Oct 11;490(7419):288-91
pubmed: 22895188
Immunol Rev. 2017 May;277(1):61-75
pubmed: 28462526
Chem Biol Drug Des. 2015 Oct;86(4):691-6
pubmed: 25677205
Nat Commun. 2020 May 5;11(1):2212
pubmed: 32371889
Biochem Biophys Res Commun. 2008 Mar 14;367(3):693-9
pubmed: 18166152
Planta Med. 1983 Apr;47(4):227-9
pubmed: 17404921
Cell. 2012 Aug 3;150(3):606-19
pubmed: 22819539
Oncol Rep. 2018 Oct;40(4):1971-1984
pubmed: 30106450
Immunity. 2018 Oct 16;49(4):740-753.e7
pubmed: 30314759
PLoS Pathog. 2014 Sep 25;10(9):e1004410
pubmed: 25254654
Cell Mol Life Sci. 2021 Feb;78(4):1233-1261
pubmed: 33057840
Immunity. 2010 Mar 26;32(3):305-15
pubmed: 20346772
Chem Pharm Bull (Tokyo). 2003 Nov;51(11):1299-300
pubmed: 14600376
Sci Rep. 2021 Jan 13;11(1):855
pubmed: 33441602
Signal Transduct Target Ther. 2021 Mar 29;6(1):128
pubmed: 33776057
Nat Immunol. 2008 Apr;9(4):361-8
pubmed: 18297073
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
PLoS Pathog. 2018 May 23;14(5):e1007105
pubmed: 29791511
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
J Leukoc Biol. 2019 Jul;106(1):147-160
pubmed: 30900780
Front Physiol. 2014 Sep 29;5:352
pubmed: 25324778
Nat Immunol. 2004 Feb;5(2):190-8
pubmed: 14716310
PLoS One. 2013 Dec 12;8(12):e80743
pubmed: 24349012
Sci Rep. 2019 Jun 24;9(1):9177
pubmed: 31235856
Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28
pubmed: 18396408
Eur J Med Chem. 2014 Jul 23;82:466-71
pubmed: 24929344
Annu Rev Immunol. 2015;33:257-90
pubmed: 25581309
Int J Biol Macromol. 2021 Sep 1;186:54-70
pubmed: 34237360
J Immunol. 2007 Feb 15;178(4):2380-6
pubmed: 17277144
PLoS One. 2013 Oct 07;8(10):e76754
pubmed: 24116148
J Immunol. 2004 Feb 15;172(4):2039-47
pubmed: 14764668
Cell. 2011 Nov 11;147(4):868-80
pubmed: 22078883
PLoS One. 2010 Apr 20;5(4):e10250
pubmed: 20422028